Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Medicine Mindmed Inc (NQ: MNMD )

7.090 -0.430 (-5.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,078,380
Open 7.400
Bid (Size) 7.080 (1)
Ask (Size) 7.150 (7)
Prev. Close 7.520
Today's Range 6.990 - 7.580
52wk Range 2.690 - 12.22
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer
From Mind Medicine (MindMed) Inc.
Via Business Wire
AI And Psychedelics: A Marriage Made In Heaven For Mental Health Care?
AI and psychedelic medicine are merging, with research showing AI's role in drug discovery, trials, and personalized mental health care. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+95.86%
+95.86%
1 Month
+12.36%
+12.36%
3 Month
+18.66%
+18.66%
6 Month
-10.82%
-10.82%
1 Year
+157.82%
+157.82%

More News

Read More
MindMed to Participate in Upcoming Investor Conferences
From Mind Medicine Inc.
Via Business Wire
MindMed Reports Third Quarter 2024 Financial Results and Business Updates
From Mind Medicine Inc.
Via Business Wire
Psychedelics Company MindMed Prices Public Offering Aiming To Raise $75M
Via Benzinga
MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update
From Mind Medicine Inc.
Via Business Wire
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
Via Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
Via Talk Markets
MindMed Announces New Employee Inducement Grants
From Mind Medicine Inc.
Via Business Wire
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
Via Talk Markets
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
MindMed to Participate in September Investor Conferences
From Mind Medicine Inc.
Via Business Wire
Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week
Via Talk Markets
Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD
Via Talk Markets
MNMD Stock Earnings: Mind Medicine Misses EPS for Q2 2024
Via InvestorPlace
MindMed Reports Second Quarter 2024 Financial Results and Business Updates
From Mind Medicine Inc.
Via Business Wire
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
From Mind Medicine (MindMed) Inc.
Via Business Wire
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
From Mind Medicine (MindMed) Inc.
Via Business Wire
MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference
From Mind Medicine Inc.
Via Business Wire
MindMed to Host Conference Call and Webcast to Discuss Second Quarter 2024 Financial Results and Provide Business Update
From Mind Medicine Inc.
Via Business Wire
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
Via Benzinga
MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer
From Mind Medicine Inc.
Via Business Wire
MindMed Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet (ODT)
From Mind Medicine Inc.
Via Business Wire
Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD
Via Talk Markets
3 Psychedelic Stocks to Ride to the Moon and Beyond
Via InvestorPlace
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.